The short version
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Nicardipine Hydrochloride
nicardipine hydrochloride · NICARDIPINE HYDROCHLORIDE 2.5 mg/mL · Injection, Solution · Intravenous · Civica, Inc.
NDC 72572-0470-10 · 10 VIAL in 1 CARTON / 10 mL in 1 VIAL · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$182.80
Reported to Texas DSHS · 2026 annual filing · Civica, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 0.1 MG
$0.070
HCPCS J2404 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$50
18 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- American Regent, Inc.United Statesmanufacture
- American Regent, Inc.United Statesanalysis
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA090534
- TE code
- AP
- Approval date
- Nov 17, 2009
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class II · OngoingApr 18, 2025American Regent, Inc. — Lack of sterility assurance: Product leakage around the vial neck, which could potentially result in a lack of sterility assurance.
- Class II · TerminatedMay 14, 2024American Regent, Inc. — Lack of Assurance of Sterility.
Manufacturers of nicardipine hydrochloride (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Baxter Healthcare Corporation | NICARDIPINE HYDROCHLORIDE .2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Baxter Healthcare Corporation | NICARDIPINE HYDROCHLORIDE .1 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Eugia US LLC | NICARDIPINE HYDROCHLORIDE 25 mg/10mL | Jul 15, 2026 | Sep 3, 2026 |
| American Regent, Inc. | NICARDIPINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Archis Pharma LLC | NICARDIPINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | NICARDIPINE HYDROCHLORIDE 2.5 mg/10mL | Jul 15, 2026 | Sep 2, 2026 |
| Civica, Inc. | NICARDIPINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Meitheal Pharmaceuticals Inc. | NICARDIPINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Qilu Pharmaceutical Co., Ltd. | NICARDIPINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | NICARDIPINE HYDROCHLORIDE 2.5 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| WG Critical Care, LLC | NICARDIPINE HYDROCHLORIDE .1 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| WG Critical Care, LLC | NICARDIPINE HYDROCHLORIDE .2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Nicardipine Hydrochloride — NDC 72572-0470-10," retrieved September 3, 2026, https://drugdashboards.com/drug/72572047010.
Free to cite with attribution — see how the data is put together.